An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
We report a patient with chronic lymphocytic leukaemia (CLL) who was treated with idelalisib, a PI3Kδ inhibitor with rituximab. After 20 weeks of treatment, the patient developed classical signs and symptoms of polymyalgia rheumatica (PMR) in association with an elevated C reactive protein of 74 mg/L. After 2 weeks of prednisolone 15 mg daily symptoms had resolved and acute phase markers normalised. To our knowledge, this is the first report of PMR developing as a complication of PI3Kδ inhibitor treatment of CLL.
Keywords:
haematology (drugs And Medicines); musculoskeletal syndromes.
Dejaco C, Singh YP, Perel P, et al. . 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015;74:1799–807. 10.1136/annrheumdis-2015-207492
-
DOI
-
PubMed
Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. . The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000;27:2179–84.
-
PubMed
Yang Q, Modi P, Newcomb T, et al. . Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res 2015;21:1537–42. 10.1158/1078-0432.CCR-14-2034
-
DOI
-
PMC
-
PubMed
Brown JR, Byrd JC, Coutre SE, et al. . Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390–7. 10.1182/blood-2013-11-535047
-
DOI
-
PMC
-
PubMed
